Insmed’s (INSM) Overweight Rating Reaffirmed at JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Insmed (NASDAQ:INSM – Free Report) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on INSM. Evercore ISI upped their price […]
More Stories
USDA Disqualifies 1,562 Retailers, Prevents $835 Million in Fraudulent SNAP Transactions
By Naveen Athrappully The U.S. Department of Agriculture’s Food and Nutrition Service has disqualified 1,562 retailers associated with the Supplemental...
Abbott Threatens $200 Million in Funding Cuts Across Texas’s Largest Cities Over ICE Policies
By Kimberly Hayek Texas Gov. Greg Abbott on April 16 threatened to cut more than $200 million in public safety...
Wall Street Review: S&P 500 Surpasses 7,100 for First Time
By Panos Mourdoukoutas Stocks extended their rebound into the third week of April, with the S&P 500 and Nasdaq reaching...
Appeals Court Allows Construction of White House Ballroom to Continue
By Aldgra Fredly A U.S. appeals court on April 17 put on hold a lower court order that had halted...
Iran Says It Closed Strait of Hormuz Again Over US Blockade
By Tom Ozimek Iran’s military said on April 18 it has reinstated “strict military oversight” over the Strait of Hormuz...
$521 Billion Fraud Landscape: What to Know
By Sylvia Xu The federal government lost up to half a trillion dollars to fraud each year over a five-year...